Zoetic (ZOE) announced that its shares will be trading on the United States OTC market on Tuesday, 12 November.
Zoetic’s shares will cross-trade on the OTCQB Venture Market, with no impact on the existing listing of its shares on the London Stock Exchange, the company said.
Nick Tulloch, Chief Executive of Zoetic International, commented on the listing: "It has been our ambition for some time to facilitate investment from the United States.”
He added: “Being the country where the majority of our operations are based, we have already attracted some interest and this week's move onto the OTC considerably simplifies the process for US investors, enabling them to trade in our shares in US dollars during US market hours.”
Zoetic said it had been exploring ways to make it easier for investors to trade in its shares in the US after an increase in interest from investors from the region.
Shares in Zoetic rose 6.52% to 12.25p during Monday morning trading
Mr. Tulloch added: “the CBD market is well developed in the US so we are optimistic that the enhanced profile that our OTC ticker will give us will generate further interest from the already established community of investors in the CBD industry. “
He also highlighted that Zoetic International “will be the first CBD company with a primary listing in London to trade on a regulated US market.”
Mr. Tulloch is attending the opening in New York on Tuesday and said he will be begin to build an investor following in the US.
Follow News & Updates from Zoetic here: